Biology is asking more of DNA
The complexity of biological research has changed dramatically over the last decade. Today's scientists are no longer focused primarily on simple constructs or straightforward design objectives. Instead, they are engineering more sophisticated DNA sequences to achieve highly specific biological outcomes.
Whether supporting cell and gene therapy discovery, optimizing metabolic pathways, engineering microbial strains, or accelerating protein discovery programs, researchers are asking more from every construct they design. A single DNA construct may now be expected to deliver multiple functions, support extensive optimization efforts, or serve as the foundation for iterative engineering workflows.
As scientific ambition grows, so do the demands placed on DNA synthesis. What was once considered an exceptional request—a highly complex, difficult-to-synthesize construct—is becoming increasingly common across research disciplines. Complexity is no longer a niche challenge; it’s a natural consequence of scientific progress.
The emergence of collaborations such as the partnership between Integrated DNA Technologies (IDT) and Ansa Biotechnologies highlights how the industry is beginning to respond to this shift by expanding researchers' access to longer and more challenging DNA constructs.
Understanding this shift begins with a simple question: What does "complex DNA" actually mean today?
What “complex DNA” really means
For many years, DNA complexity was often measured by one characteristic: length. Today, that definition is no longer sufficient. Modern construct complexity can arise from numerous sequence features, including:
- High or low GC content
- Repetitive elements
- Homopolymers
- Sequence features associated with secondary structure formation
- Inverted repeats
- Multi-fragment assemblies
- Combinatorial edits
- Functionally constrained sequences
- Highly optimized designs that leave little room for modification
In reality, many constructs combine several of these characteristics simultaneously.
This broader understanding of complexity matters because some of the most challenging constructs are not necessarily the longest ones. Instead, the greatest manufacturing difficulties often stem from sequence architecture and sequence-specific constraints.
This is why innovations aimed at supporting difficult motifs, repetitive regions, homopolymers, and GC-rich sequences are becoming more and more important. The IDT–Ansa collaboration reflects this growing need by helping address both construct length and sequence complexity together.
Why construct ambition is increasing
The rise in sequence complexity is not happening by accident. Synthetic biology workflows continue to become more sophisticated across discovery, engineering, and optimization. Researchers across a many fields—including protein engineering, metabolic pathway design, assay development, functional genomics, among others—need a single construct to accomplish more while supporting faster development timelines and more targeted outcomes.
Scientists are continually pushing toward designs that offer greater precision and performance, reflecting the evolving demands of modern biological research. As programs become more ambitious, DNA constructs become more sophisticated, and the limitations of traditional synthesis approaches become increasingly visible.
Where traditional synthesis workflows start to struggle
Many conventional DNA synthesis workflows are best suited to more standardized construct requirements.
As complexity increases, researchers often encounter new challenges:
- Reduced manufacturability
- Additional redesign requests
- Extended timelines
- Lower predictability
- Increased troubleshooting requirements
In many cases, synthesizing a sequence is only the first step. The greater challenge lies in navigating the synthesis workflow efficiently and reliably while preserving the integrity of the original design.
This is becoming a critical pressure point for researchers. As projects become more dependent on complex constructs, workflow inefficiencies can have a cascading impact throughout downstream research activities.
These realities help drive interest in new synthesis approaches and collaborations designed to address complex construct requirements.
The hidden cost of complexity bottlenecks
The consequences of synthesis challenges extend beyond manufacturing. Delays in construct delivery can slow experiments, postpone decision-making, and disrupt project momentum.
Repeated redesign cycles can consume valuable time while forcing teams to make compromises that diverge from their original objectives. In some cases, researchers may alter designs primarily to accommodate manufacturing limitations rather than scientific intent.
Uncertainty creates an additional burden. When design feasibility or delivery timelines are difficult to predict, planning becomes more complicated. Researchers may struggle to coordinate resources, sequence experiments, or maintain development schedules.
As a result, organizations are evaluating synthesis partners on technical capability and on their ability to reduce downstream rework and improve confidence throughout the design-to-build process.
Why a clearer path to complexity matters now
As complex constructs become more common, researchers need workflows that support challenging designs from the beginning rather than treating complexity as an exception.
A clearer path to complexity includes:
- Better upfront assessment of manufacturability
- Earlier visibility into design risks
- Fewer avoidable redesign cycles
- Clearer expectations around feasibility and timing
- More predictable delivery outcomes
Importantly, the industry's challenge is no longer simply one of capacity. Researchers need confidence that complex constructs can be synthesized accurately and reliably while preserving design intent.
Across the synthetic biology landscape, new technologies and strategic collaborations are emerging to meet this need. The IDT–Ansa collaboration provides one example of how the market is evolving to support increasingly demanding construct requirements.
The IDT–Ansa partnership: A response to rising DNA complexity
The collaboration between IDT and Ansa reflects a broader industry movement toward supporting longer, more complex DNA constructs with greater reliability.
Through this collaboration, IDT customers gain access to sequence-verified Clonal DNA and XL Clonal DNA products ranging from 100 bp to 50 kb, significantly expanding what researchers can pursue through a single trusted provider.
Our partnership is specifically designed to help address persistent synthesis challenges associated with:
- GC-rich regions
- Homopolymers
- Repetitive elements
- Difficult sequence motifs
- Long construct requirements
By combining IDT's longstanding genomics expertise, global reach, and customer support with Ansa's enzymatic DNA synthesis platform, researchers gain access to a workflow focused on length, complexity, speed, and reliability.
The practical value is straightforward: greater confidence in design fidelity, fewer avoidable redesign cycles, and a more predictable path from concept to construct.
Rather than representing a standalone solution, the collaboration serves as an example of how synthesis technologies are evolving to help researchers pursue ambitious biological designs without compromise.
What researchers should look for in a synthesis partner
As DNA complexity becomes more commonplace, selecting the right synthesis partner is becoming more important than ever.
Researchers should look for partners that offer:
- Support for challenging sequence architectures: The ability to handle difficult motifs, repetitive regions, and unconventional designs is becoming critical.
- Early design guidance: Identifying manufacturability risks before synthesis begins can help preserve timelines and reduce downstream revisions.
- Transparent expectations: Clear communication around feasibility, risk, and delivery helps teams plan more effectively.
- Reliability from design to delivery: Technical capability alone is not enough. Researchers need clear expectations, sequence verification, and confidence that delivered constructs are ready for downstream workflows.
Complexity is becoming the new normal
The future of biology will continue to be shaped by progressively sophisticated DNA designs.
As research programs pursue more ambitious goals, the ability to move efficiently from design to build becomes increasingly important. Teams that can navigate construct complexity with greater predictability are better positioned to maintain momentum, reduce avoidable redesign cycles, and preserve the integrity of their original designs.
The challenge is no longer whether complex DNA will become commonplace. It already is.
The IDT-Ansa partnership reflects how DNA synthesis is evolving to support this shift—expanding access to longer, more complex, sequence-verified clonal DNA so researchers can push the boundaries of what's possible in modern biology.
